[Tianeptin (coaxil) in therapy of depression in cardiovascular patients].
To study clinical efficacy, tolerance and safety of antidepressant coaxil in the treatment of patients with cardiovascular disease (CVD) and depression; to compare efficacy of combined (somatotropic plus psychotropic) therapy and monotherapy with somatotropic drugs in the above diseases. Of 86 participants of the study, 24 had arterial hypertension (AH) and depression, 25--AH, coronary artery disease and depression. They received combined treatment. 37 patients of the control subgroups received monotherapy. Somatic condition of the patients was examined with clinical, device and laboratory methods, antidepressant efficiency was examined with the clinicopsychopathological method and psychometric scales--HDRS, HARS, MADRS and CGI-S. Combined treatment with coaxil provided target blood pressure in 79.5% patients, monotherapy--in 65.7%. The response in the test subgroups reached 73.9 and 64.0%. By side effects, the difference between the groups was not significant. Somatotropic monotherapy in most control patients failed to reduce psychopathological disorders. Combined treatment with coaxil proved more effective than somatotropic monotherapy in CVD patients with depression. Coaxil treatment is safe as it has no side effects.